BioAtla Files 8-K for Material Agreement
Ticker: BCAB · Form: 8-K · Filed: Sep 23, 2024 · CIK: 1826892
Sentiment: neutral
Topics: material-agreement, filing, corporate-update
TL;DR
BioAtla signed a big deal, filing an 8-K today.
AI Summary
On September 23, 2024, BioAtla, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company is incorporated in Delaware and its principal executive offices are located at 11085 Torreyana Road, San Diego, California.
Why It Matters
This filing indicates a significant contractual development for BioAtla, Inc., which could impact its operations, partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that are not yet fully understood by the market.
Key Numbers
- 001-39787 — SEC File Number (Identifies the company's filing with the SEC.)
- 85-1922320 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- BioAtla, Inc. (company) — Registrant
- September 23, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 11085 Torreyana Road, San Diego, California 92121 (address) — Principal Executive Offices
- 858 558-0708 (phone_number) — Registrant's Telephone Number
FAQ
What is the nature of the material definitive agreement filed by BioAtla, Inc.?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 23, 2024.
Where are BioAtla, Inc.'s principal executive offices located?
BioAtla, Inc.'s principal executive offices are located at 11085 Torreyana Road, San Diego, California 92121.
What is BioAtla, Inc.'s SEC file number?
BioAtla, Inc.'s SEC file number is 001-39787.
What is the SIC code for BioAtla, Inc.?
The Standard Industrial Classification (SIC) code for BioAtla, Inc. is 2836, which corresponds to Biological Products (No Diagnostic Substances).
Filing Stats: 1,059 words · 4 min read · ~4 pages · Grade level 14.8 · Accepted 2024-09-23 07:48:31
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share BCAB Nasdaq Glo
- $133.5 million — he Company is eligible to receive up to $133.5 million in aggregate payments, including $15.0
- $15.0 million — illion in aggregate payments, including $15.0 million in upfront and near-term milestones and
- $118.5 million — near-term milestones and an additional $118.5 million in milestone payments based upon the ac
Filing Documents
- d845616d8k.htm (8-K) — 31KB
- d845616dex101.htm (EX-10.1) — 348KB
- d845616dex102.htm (EX-10.2) — 369KB
- 0001193125-24-223282.txt ( ) — 1011KB
- bcab-20240923.xsd (EX-101.SCH) — 3KB
- bcab-20240923_lab.xml (EX-101.LAB) — 17KB
- bcab-20240923_pre.xml (EX-101.PRE) — 11KB
- d845616d8k_htm.xml (XML) — 3KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1* License Agreement between BioAtla, Inc. and Context Therapeutics Inc., dated as of September 23, 2024 10.2* Global Transaction Agreement between BioAtla, Inc. and Himalaya Therapeutics SEZC, dated as of September 23, 2024 104 Cover Page Interactive Data File-the cover page XBRL tags are embedded within the Inline XBRL document. * Portions of this exhibit have been redacted in accordance with Item 601(b)(10)(iv) of Regulation S-K.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BioAtla, Inc. Date: September 23, 2024 By: /s/ Richard Waldron Richard Waldron Chief Financial Officer